Magazine
The Third Wave copied information from Psychedelic.Support and MAPS Integration List without permission to use for its own directory.
Magazine
News that COMPASS Pathways is attempting to patent psychedelic therapy room specifications and therapist behaviors started an online firestorm about the company’s “monopolistic and shady behaviors,” but so far the debates have missed the biggest threats lurking in COMPASS’s international patent appl
Magazine
On January 6th, 2021 at least two psychedelic heads stormed the United States Capitol. Strange as it may seem, those adhering to right-wing politics haven’t just established a beachhead in the psychedelic renaissance—they’re maneuvering to own it.
Magazine
Weeoo weeoo livestream alert for Thursday, December 17th at 8PM ET!!. Last time we popped bottles and jammed in the comments – come hang out with us again for some reflections on 2020.
Magazine
Thea Riofrancos is a political scientist whose research has focused on political conflict related to extraction, energy, and infrastructure in a rapidly warming and politically unstable world. She also serves on the steering committee for Democratic Socialists of America for a Green New Deal.
Magazine
This list is by no means exhaustive, but it spotlights a number of psychedelic pharmaceutical companies and executives with ties to extractive industry.
Magazine
Extractive industry is highly speculative by nature and firms are risk tolerant—they either “strike gold” or they don’t. When their gambles fail, psychedelic startups can take over their corporate shells to quickly go public with minimal regulatory scrutiny.
Magazine
A mining firm’s conflict with Argentinian communities illustrates extractive industry’s practices and values, and raises questions about how these corporate approaches will translate into the psychedelic pharmaceutical industry.
Magazine
Canadian mining and exploration company AIS has had a number of executives move on to found psychedelic pharmaceutical businesses. Why? Because psychedelics are where the money’s at.
Magazine
When the media republishes statements from psychedelic pharmaceutical startups and their executives with little-to-no vetting, it functions as a corporate megaphone and damages the field of psychedelic science.
Magazine
Through EmpathBio, ATAI Life Sciences says it will develop “safer” MDMA derivatives for patients with PTSD and calls the Multidisciplinary Association for Psychedelic Studies’ (MAPS) approach “MDMA 1.0.” MAPS’ executive director, Rick Doblin, says that if that’s the case, ATAI is “MDMA 0.5.”
Magazine
Since COMPASS Pathways filed for a controversial psilocybin patent in 2018, Usona Institute has consistently placed its research findings in the public domain.